Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study

被引:9
作者
Hudson, Marie [1 ,2 ]
Dell'Aniello, Sophie [1 ]
Shen, Sophie [3 ]
Simon, Teresa A. [3 ]
Ernst, Pierre [1 ,4 ]
Suissa, Samy [1 ,5 ]
机构
[1] Lady Davis Inst Jewish Gen Hosp, Ctr Clin Epidemiol, Montreal, PQ, Canada
[2] Jewish Gen Hosp, Div Rheumatol, Montreal, PQ, Canada
[3] Bristol Myers Squibb, Global Pharmacovigilance & Epidemiol, Hopewell, NJ USA
[4] Jewish Gen Hosp, Div Resp Med, Montreal, PQ, Canada
[5] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada
基金
加拿大健康研究院;
关键词
INFECTION; RISK; COMORBIDITY; MORTALITY; COHORT;
D O I
10.1093/rheumatology/kez359
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. Abatacept, a biologic DMARD, was associated with respiratory adverse events in a small subgroup of RA patients with chronic obstructive pulmonary disease (COPD) in a trial. Whether this potential risk is specific to abatacept or extends to all biologics and targeted synthetic DMARDs (tsDMARDs) is unclear. We assessed the risk of adverse respiratory events associated with biologic and tsDMARDs compared with conventional synthetic DMARDs (csDMARDs) among RA patients with concomitant COPD in a large, real-world cohort. Methods. We used a prevalent new-user design to study RA patients with COPD in the US-based MarketScan databases. New users of biologic DMARDs and/or tsDMARDs were matched on time-conditional propensity scores to new users of csDMARDs. Adverse respiratory events were estimated using Cox models comparing current use of biologic/tsDMARDs with csDMARDs. Results. The cohort included 7424 patients initiating biologic/tsDMARDs and 7424 matched patients initiating csDMARDs. The adjusted hazard ratio of hospitalized COPD exacerbation comparing biologic/tsDMARD vs csDMARD was 0.76 (95% CI: 0.55, 1.06), while it was 1.02 (95% CI: 0.82, 1.27) for bronchitis, 1.21 (95% CI: 0.92, 1.58) for hospitalized pneumonia or influenza and 0.99 (95% CI: 0.87, 1.12) for outpatient pneumonia or influenza. The hazard ratio of the combined end point of COPD exacerbation, bronchitis and hospitalized pneumonia or influenza was 1.04 (95% CI: 0.89, 1.21). Conclusion. In this large, real-world comparative safety study, biologic and tsDMARDs, including abatacept, were not associated with an increased risk of adverse respiratory events when compared with csDMARDs in patients with RA and COPD.
引用
收藏
页码:820 / 827
页数:8
相关论文
共 50 条
  • [31] Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD Cohort Study in Real-World Clinical Practice
    Suissa, Samy
    Dell'Aniello, Sophie
    Ernst, Pierre
    CHEST, 2020, 157 (04) : 846 - 855
  • [32] Comparative safety performance of autonomous- and human drivers: A real-world case study of the Waymo Driver
    Di Lillo, Luigi
    Gode, Tilia
    Zhou, Xilin
    Atzei, Margherita
    Chen, Ruoshu
    Victor, Trent
    HELIYON, 2024, 10 (14)
  • [33] Safety of Metformin in Psoriasis Patients With Diabetes Mellitus: A 17-Year Population-Based Real-World Cohort Study
    Su, Yu-Jih
    Chen, Tien-Hsing
    Hsu, Chung-Yuan
    Chiu, Wen-Tsen
    Lin, Yu-Sheng
    Chi, Ching-Chi
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (08) : 3279 - 3286
  • [34] Outcome of Patients with Rheumatoid Arthritis: Cross-Sectional Study of a Single-Center Real-World Inception Cohort
    Ling, Eduard
    Ofer-Shiber, Shachaf
    Goren, Or
    Molad, Yair
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2013, 15 (12): : 758 - 762
  • [35] Impact of Kawasaki disease on juvenile idiopathic arthritis in real-world patients: A population-based cohort study
    Liao, Li-Chin
    Fu, Yi-Hsiu
    Chuang, Chieh-Mao
    Liao, Pei-Lun
    Wei, James Cheng-Chung
    Fu, Yun-Ching
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [36] The Relationship of Acupuncture Use to the Endometriosis Risk in Females With Rheumatoid Arthritis: Real-World Evidence From Population-Based Health Claims
    Chen, Wei-Jen
    Livneh, Hanoch
    Hsu, Chien-Hui
    Hu, Ying-To
    Lai, Ning-Sheng
    Guo, How-Ran
    Tsai, Tzung-Yi
    FRONTIERS IN MEDICINE, 2021, 7
  • [37] Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study
    Hougen, Ingrid
    Whitlock, Reid H.
    Komenda, Paul
    Rigatto, Claudio
    Clemens, Kristin K.
    Tangri, Navdeep
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (02)
  • [38] A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort
    Tageldin, Mohamed
    Wilson, Nicole
    Yin, Yue
    Sharma, Tarun S.
    RHEUMATOLOGY, 2023, 62 : IV8 - IV13
  • [39] Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score-matched study
    Pape, Katrin
    Rolfes, Leoni
    Steffen, Falk
    Muthuraman, Muthuraman
    Korsen, Melanie
    Meuth, Sven G. G.
    Zipp, Frauke
    Bittner, Stefan
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2022, 15
  • [40] Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study
    de Vlam, Kurt
    Toukap, Adrien Nzeusseu
    Kaiser, Marie-Joelle
    Vanhoof, Johan
    Remans, Philip
    Van den Berghe, Marthe
    Di Romana, Silvana
    Van den Bosch, Filip
    Lories, Rik
    ADVANCES IN THERAPY, 2022, 39 (02) : 1055 - 1067